
Lei Yao
Examiner (ID: 12775, Phone: (571)272-3112 , Office: P/1642 )
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1642 |
| Total Applications | 1328 |
| Issued Applications | 662 |
| Pending Applications | 127 |
| Abandoned Applications | 552 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 10919183
[patent_doc_number] => 20140322201
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-10-30
[patent_title] => 'METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 14/139096
[patent_app_country] => US
[patent_app_date] => 2013-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 9780
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14139096
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/139096 | METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES | Dec 22, 2013 | Abandoned |
Array
(
[id] => 9615758
[patent_doc_number] => 20140205616
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-07-24
[patent_title] => 'COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR'
[patent_app_type] => utility
[patent_app_number] => 14/109213
[patent_app_country] => US
[patent_app_date] => 2013-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 45
[patent_figures_cnt] => 45
[patent_no_of_words] => 79689
[patent_no_of_claims] => 43
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14109213
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/109213 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | Dec 16, 2013 | Abandoned |
Array
(
[id] => 10911780
[patent_doc_number] => 20140314794
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-10-23
[patent_title] => 'COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR'
[patent_app_type] => utility
[patent_app_number] => 14/108820
[patent_app_country] => US
[patent_app_date] => 2013-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 45
[patent_figures_cnt] => 45
[patent_no_of_words] => 79677
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14108820
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/108820 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | Dec 16, 2013 | Abandoned |
Array
(
[id] => 16956067
[patent_doc_number] => 11059910
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-13
[patent_title] => Anti-CD47 antibodies and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 14/095395
[patent_app_country] => US
[patent_app_date] => 2013-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 32
[patent_no_of_words] => 41578
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 174
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14095395
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/095395 | Anti-CD47 antibodies and methods of use thereof | Dec 2, 2013 | Issued |
Array
(
[id] => 14883549
[patent_doc_number] => 10421801
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-09-24
[patent_title] => Cytotoxic factors for modulating cell death
[patent_app_type] => utility
[patent_app_number] => 14/075994
[patent_app_country] => US
[patent_app_date] => 2013-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 19
[patent_no_of_words] => 15632
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14075994
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/075994 | Cytotoxic factors for modulating cell death | Nov 7, 2013 | Issued |
Array
(
[id] => 9839769
[patent_doc_number] => 20150031851
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-01-29
[patent_title] => 'HMGN2 PEPTIDES AND RELATED MOLECULES THAT SELECTIVELY HOME TO TUMOR BLOOD VESSELS AND TUMOR CELLS'
[patent_app_type] => utility
[patent_app_number] => 14/067858
[patent_app_country] => US
[patent_app_date] => 2013-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 20919
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14067858
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/067858 | HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells | Oct 29, 2013 | Issued |
Array
(
[id] => 9560678
[patent_doc_number] => 20140178391
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-06-26
[patent_title] => 'COLON DISEASE TARGETS AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 14/057434
[patent_app_country] => US
[patent_app_date] => 2013-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 41919
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14057434
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/057434 | COLON DISEASE TARGETS AND USES THEREOF | Oct 17, 2013 | Abandoned |
Array
(
[id] => 10380697
[patent_doc_number] => 20150265704
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-09-24
[patent_title] => 'IGM THERAPY IN PREVENTION OF ONSET, PROGRESSION, AND RECURRENCE OF AUTOIMMUNE TYPE 1 DIABETES'
[patent_app_type] => utility
[patent_app_number] => 14/434179
[patent_app_country] => US
[patent_app_date] => 2013-10-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 25418
[patent_no_of_claims] => 48
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14434179
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/434179 | IGM THERAPY IN PREVENTION OF ONSET, PROGRESSION, AND RECURRENCE OF AUTOIMMUNE TYPE 1 DIABETES | Oct 7, 2013 | Abandoned |
Array
(
[id] => 9269670
[patent_doc_number] => 20140024588
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-01-23
[patent_title] => 'METHOD FOR INDUCING SUSTAINED IMMUNE RESPONSE'
[patent_app_type] => utility
[patent_app_number] => 14/045576
[patent_app_country] => US
[patent_app_date] => 2013-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5820
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14045576
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/045576 | METHOD FOR INDUCING SUSTAINED IMMUNE RESPONSE | Oct 2, 2013 | Abandoned |
Array
(
[id] => 10529006
[patent_doc_number] => 09255134
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-02-09
[patent_title] => 'Lytic domain fusion constructs and methods of making and using same'
[patent_app_type] => utility
[patent_app_number] => 14/038631
[patent_app_country] => US
[patent_app_date] => 2013-09-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 33
[patent_no_of_words] => 29648
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14038631
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/038631 | Lytic domain fusion constructs and methods of making and using same | Sep 25, 2013 | Issued |
Array
(
[id] => 12037647
[patent_doc_number] => 09815866
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-11-14
[patent_title] => 'Peptides that bind to epithelial cell adhesion molecule'
[patent_app_type] => utility
[patent_app_number] => 14/428017
[patent_app_country] => US
[patent_app_date] => 2013-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 26
[patent_no_of_words] => 9301
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14428017
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/428017 | Peptides that bind to epithelial cell adhesion molecule | Sep 11, 2013 | Issued |
Array
(
[id] => 9449373
[patent_doc_number] => 20140120543
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-05-01
[patent_title] => 'EXPRESSION OF ISOFORM 202 OF ERCC1 FOR PREDICTING RESPONSE TO CANCER CHEMOTHERAPY'
[patent_app_type] => utility
[patent_app_number] => 14/021316
[patent_app_country] => US
[patent_app_date] => 2013-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 11235
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14021316
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/021316 | EXPRESSION OF ISOFORM 202 OF ERCC1 FOR PREDICTING RESPONSE TO CANCER CHEMOTHERAPY | Sep 8, 2013 | Abandoned |
Array
(
[id] => 9306012
[patent_doc_number] => 20140044686
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-02-13
[patent_title] => 'MOLECULAR MARKER FOR CANCER STEM CELL'
[patent_app_type] => utility
[patent_app_number] => 13/967410
[patent_app_country] => US
[patent_app_date] => 2013-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 15510
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13967410
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/967410 | Molecular marker for cancer stem cell | Aug 14, 2013 | Issued |
Array
(
[id] => 10654739
[patent_doc_number] => 20160000884
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-01-07
[patent_title] => 'Liquid Factor VIII Formulations'
[patent_app_type] => utility
[patent_app_number] => 14/420564
[patent_app_country] => US
[patent_app_date] => 2013-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15474
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14420564
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/420564 | Liquid Factor VIII Formulations | Aug 12, 2013 | Abandoned |
Array
(
[id] => 9634309
[patent_doc_number] => 20140212418
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-07-31
[patent_title] => 'Therapeutic Antibodies'
[patent_app_type] => utility
[patent_app_number] => 13/955785
[patent_app_country] => US
[patent_app_date] => 2013-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 7693
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13955785
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/955785 | Therapeutic Antibodies | Jul 30, 2013 | Abandoned |
Array
(
[id] => 10325993
[patent_doc_number] => 20150210997
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-07-30
[patent_title] => 'METHODS AND COMPOUNDS FOR REDUCING THREONYL-tRNA SYNTHETASE ACTIVITY'
[patent_app_type] => utility
[patent_app_number] => 14/416356
[patent_app_country] => US
[patent_app_date] => 2013-07-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 37233
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 12
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14416356
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/416356 | Methods and compounds for reducing threonyl-tRNA synthetase activity | Jul 23, 2013 | Issued |
Array
(
[id] => 9222479
[patent_doc_number] => 20140017254
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-01-16
[patent_title] => 'Identification of Tumor-Associated Antigens for Diagnosis and Therapy'
[patent_app_type] => utility
[patent_app_number] => 13/946302
[patent_app_country] => US
[patent_app_date] => 2013-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 46
[patent_figures_cnt] => 46
[patent_no_of_words] => 23462
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 17
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13946302
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/946302 | Identification of Tumor-Associated Antigens for Diagnosis and Therapy | Jul 18, 2013 | Abandoned |
Array
(
[id] => 10281667
[patent_doc_number] => 20150166664
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-06-18
[patent_title] => 'NOVEL THERAPEUTIC TREATMENTS WITH ANTI-HER2 ANTIBODIES HAVING A LOW FUCOSYLATION'
[patent_app_type] => utility
[patent_app_number] => 14/412797
[patent_app_country] => US
[patent_app_date] => 2013-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 46856
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14412797
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/412797 | NOVEL THERAPEUTIC TREATMENTS WITH ANTI-HER2 ANTIBODIES HAVING A LOW FUCOSYLATION | Jul 17, 2013 | Abandoned |
Array
(
[id] => 9318406
[patent_doc_number] => 20140050744
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-02-20
[patent_title] => 'COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR'
[patent_app_type] => utility
[patent_app_number] => 13/945052
[patent_app_country] => US
[patent_app_date] => 2013-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 45
[patent_figures_cnt] => 45
[patent_no_of_words] => 79664
[patent_no_of_claims] => 43
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13945052
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/945052 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | Jul 17, 2013 | Abandoned |
Array
(
[id] => 9147811
[patent_doc_number] => 20130302334
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-11-14
[patent_title] => 'BCL-2-LIKE PROTEIN 11 SRM/MRM ASSAY'
[patent_app_type] => utility
[patent_app_number] => 13/942574
[patent_app_country] => US
[patent_app_date] => 2013-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8954
[patent_no_of_claims] => 37
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13942574
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/942574 | BCL-2-like protein 11 SRM/MRM assay | Jul 14, 2013 | Issued |